Axcella Health Inc (AXLA)

Etorro trading 970x250
Axcella Health Inc (AXLA) Logo

About Axcella Health Inc

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company’s lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. It also develops AXA4010, a hematology product candidate; and AXA2678, a muscle product candidate. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts. Address: 840 Memorial Drive, Cambridge, MA, United States, 02139

Axcella Health Inc News and around…

Latest news about Axcella Health Inc (AXLA) common stock and company :

12 Health Care Stocks Moving In Friday's After-Market Session
12 Aug, 2022 FinancialContent

Gainers Axcella Health (NASDAQ:AXLA) shares rose 25.5% to $3.0 during Friday's after-market session. The market ...

Axcella Health: Q2 Earnings Insights
12 Aug, 2022 FinancialContent

Axcella Health (NASDAQ:AXLA) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here's what ...

Axcella Reports Second Quarter Financial Results and Provides Business Update
12 Aug, 2022 FinancialContent

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.

The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics
10 Aug, 2022 Yahoo! Finance

Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
09 Aug, 2022 Yahoo! Finance

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

The Petri Dish: Axcella advances long Covid drug
04 Aug, 2022 Yahoo! Finance

Flagship Pioneering spinout Axcella Therapeutics Inc. has promising results from a small Phase 2a study investigating a drug for long Covid.

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
02 Aug, 2022 FinancialContent

Avalo Therapeutics (NASDAQ: AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of ...

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
02 Aug, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Allarity To Shift Focus On ...

Axcella's NASH Candidate Shows Favorable Action In Long COVID-Related Fatigue
02 Aug, 2022 FinancialContent

Axcella Health Inc(NASDAQ: AXLA) hasreported topline resultsfrom the Phase 2a study to evaluate the efficacy and ...

Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
02 Aug, 2022 FinancialContent

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today reported topline results from the Phase 2a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID.

Axcella long COVID treatment helps some patients in small trial
02 Aug, 2022 Yahoo! Finance

One of the first trials aimed at tackling long COVID helped some patients recover from lingering physical and mental fatigue, although the drug developed by Axcella Health Inc failed on the small study's main goal of restoring the normal function of mitochondria - the energy factories of cells. In the 41-patient pilot study released on Tuesday, for three of 21 patients who received the drug, AXA1125, their physical fatigue scores returned to normal levels after 28 days of treatment, Axcella Chief Medical Officer Margaret Koziel said in a phone interview. Others who received the drug also reported physical and mental improvements that were deemed to be statistically significant as shown on a scale developed to measure chronic fatigue, according to the preliminary results, and the drug was shown to be safe and well tolerated.

Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
02 Aug, 2022 Yahoo! Finance

CAMBRIDGE, Mass., August 02, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today reported topline results from the Phase 2a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID.

Great news for Axcella Health Inc. (NASDAQ:AXLA): Insiders acquired stock in large numbers last year
01 Jul, 2022 Yahoo! Finance

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
27 Jun, 2022 FinancialContent

A handful of small companies are working on long Covid treatments — sorely needed tools as the number of those afflicted grows.

89 Biggest Movers From Friday
21 Jun, 2022 FinancialContent

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 ...

91 Biggest Movers From Friday
13 Jun, 2022 FinancialContent

Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced ...

12 Health Care Stocks Moving In Friday's Intraday Session
10 Jun, 2022 FinancialContent

Gainers Cogent Biosciences (NASDAQ:COGT) shares increased by 76.6% to $8.76 during Friday's regular session. As of ...

Axcella (AXLA) Up on Decision to Prioritize Long-COVID Program
27 May, 2022 Yahoo! Finance

Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 studies.

Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
26 May, 2022 FinancialContent

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has prioritized its clinical development portfolio after rapid enrollment for its Phase 2a clinical trial in Long COVID. The company affirmed topline data readout for its Phase 2a Long COVID trial in early Q3 2022 and interim data readout for NASH in late Q3 2022. The company is suspending its Phase 2 clinical trial in OHE (Overt Hepatic Encephalopathy) while exploring potential partnership for the program.

Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
19 May, 2022 FinancialContent

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place May 23 – 26, 2022 both virtually and in-person in Miami, Florida.

Recap: Axcella Health Q1 Earnings
05 May, 2022 FinancialContent

Axcella Health (NASDAQ:AXLA) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what ...

Axcella Reports First Quarter Financial Results and Provides Business Update
05 May, 2022 FinancialContent

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

Zosano (ZSAN) to Report Q1 Earnings: What's in the Cards?
28 Apr, 2022 Yahoo! Finance

Zosano (ZSAN) is set to provide updates on the development path ahead for its lead candidate, M207, when it reports earnings results for first-quarter 2022.

Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon
20 Apr, 2022 Yahoo! Finance

The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly.

TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down
19 Apr, 2022 Yahoo! Finance

TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.

Can Tenet Healthcare (THC) Post Q1 Earnings Beat on Low Costs?
18 Apr, 2022 Yahoo! Finance

Tenet Healthcare's (THC) first-quarter 2022 results are likely to reflect an improvement in adjusted admissions and outpatient admissions.

Moderna (MRNA) Initiates Early-Stage Flu Vaccine Study
12 Apr, 2022 Yahoo! Finance

Moderna's (MRNA) two vaccine candidates, mRNA-1020 and mRNA-1030, target both hemagglutinin and neuraminidase protein for providing better protection against the influenza virus. The company initiates a phase I/II study.

Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study
07 Apr, 2022 Yahoo! Finance

Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.

Rhythm Pharmaceuticals (RYTM) Down Due to Study Design Changes
07 Apr, 2022 Yahoo! Finance

Rhythm Pharmaceuticals (RYTM) modifies the design of its two genetic obesity disorder studies to focus on rare patients, thus reducing the targeted population size. RYTM expects to save costs in the process.

Earnings Scheduled For March 30, 2022
30 Mar, 2022 FinancialContent

Companies Reporting Before The Bell • Orgenesis (NASDAQ:ORGS) is likely to report earnings for its fourth ...

Axcella Health Inc (AXLA) is a NASDAQ Common Stock listed in , ,

970x250